Why meniscus tears so often leave cartilage damage behind

A meniscus tear rarely travels alone. The two crescent-shaped pads of cartilage inside the knee — the menisci — act as shock absorbers and load spreaders, distributing force evenly across the joint surface with every step. When a tear disrupts that function, stress concentrates on a narrower area of the articular cartilage underneath. Over time, that localised overload can produce a focal chondral defect: a patch of surface cartilage that thins or breaks down in the zone where the meniscus is no longer doing its job.

The medial (inner) compartment is particularly vulnerable. Co-occurring medial meniscus tear and focal damage to the medial femoral condyle — the rounded lower end of the thigh bone — is a well-recognised clinical pattern, not an unusual finding.

Managing the meniscus itself addresses one problem, but it does not automatically resolve any cartilage damage that was already present. Partial meniscectomy can relieve short-term pain, yet studies suggest it may accelerate focal cartilage wear over 5–12 years in the affected compartment, precisely because the meniscal cushion is reduced rather than restored.

For patients who continue to experience knee pain or swelling after their meniscus has been treated, residual focal cartilage damage is a plausible explanation worth investigating. Identifying and addressing it early matters: untreated focal defects can progress, gradually widening the area of damage and increasing the risk of more widespread osteoarthritis.

What ChondroFiller (Liquid Cartilage) is and how the scaffold works

ChondroFiller® liquid — marketed in the UK as Liquid Cartilage™ — holds CE-mark status as a Class III medical device, the same regulatory tier as cardiac implants and joint prostheses. That classification reflects the rigorous conformity assessment applied to devices that interact directly with living tissue over an extended period.

The product itself is a purified Type I collagen, acid-extracted from murine sources, supplied as a liquid that becomes a firm gel within minutes of entering the joint environment. Once placed into a focal cartilage defect, it bonds to the surrounding tissue and physically occupies the void — but that structural role is only the beginning.

The governing principle is acellular matrix-induced chondrogenesis: the scaffold contains no cells of its own; instead, it creates the biochemical and physical conditions that draw the patient's own progenitor cells — from the synovial lining and subchondral bone nearby — into the defect. Those recruited cells progressively differentiate into chondrocytes, the specialised cells responsible for producing cartilage matrix. Over several months the collagen scaffold is gradually resorbed as the body's own repair tissue takes its place. This is not a permanent filler but a temporary framework that supports the body's own repair processes.

At MSK Doctors, ChondroFiller is delivered as an ultrasound-guided outpatient injection, placed precisely into the defect without the need for joint drying, debridement, or any surgical preparation. Patients typically leave the clinic on the same day.

Which patients are — and are not — suitable candidates

Not every painful knee qualifies, and the evidence is clear about where the boundaries lie.

The strongest case for ChondroFiller is a focal Grade I–III chondral defect in an otherwise reasonably preserved joint. Advanced osteoarthritis — diffuse joint-space narrowing, bone-on-bone contact, or widespread cartilage loss — is a consistent contraindication across every joint studied. The hip cohort data are instructive: at three-to-five-year follow-up, patients with Tönnis Grade 2–3 osteoarthritis had poor outcomes, while those with contained focal lesions fared well. The same principle applies in the knee.

For patients who have had a meniscus repair or partial meniscectomy, the relevant question is whether what remains is a discrete, bounded defect rather than diffuse compartmental degeneration. The clinical rationale for using ChondroFiller in this group is strong — the load-distribution deficit left by meniscal surgery creates exactly the localised focal defect the scaffold is designed for — even though a dedicated study in post-meniscus-surgery patients has not yet been published.

The 2024 knee chondroplasty study enrolled patients with a mean age of 31, and younger, active individuals do form the best-evidenced cohort. Age alone, however, is not a disqualifying factor; joint condition matters more than the number on a birth certificate.

Finally, outcome depends partly on technique: the scaffold must fill the defect flush to the surface. Overfilling reliably produces fibrous rather than hyaline-like repair tissue, as the wrist study confirmed. Precise placement under ultrasound guidance is therefore not a procedural nicety — it is a determinant of result.

What the clinical evidence shows for knee cartilage defects

Across four published knee studies, ChondroFiller has produced a mean IKDC improvement of roughly 30 points — a figure that matters because the minimum change a patient actually notices in daily function is 16.7 points. Every study in the knee has cleared that threshold.

The most substantial dataset comes from Jerosch et al.'s prospective post-market follow-up: patients gained an average of 32.4 IKDC points, reaching a final functional score of 80, and that improvement held at three-year follow-up without meaningful deterioration. In the 2024 Bulgarian knee chondroplasty series (17 patients, mean age 31), both Lysholm and IKDC scores improved significantly at three and six months, with the steepest gains between months three and six and a plateau thereafter — a pattern consistent with an active repair process settling into maturity.

MRI data add structural weight to those patient-reported numbers. MOCART scores across European knee studies ranged from 81.6 to 84.3, indicating more than 80% defect filling and good integration with the surrounding native cartilage. Notably, MOCART rose from 65.3 at four weeks to 81.6 at one year, which supports an ongoing repair process rather than a static fill — the scaffold is still being remodelled months after injection.

The 2016 multicenter randomised trial compared ChondroFiller directly with microfracture — a surgical procedure requiring joint entry, debridement, and bone perforation. All ChondroFiller-treated defects filled immediately; IKDC improved significantly at three, six, and twelve months, with no adverse events reported. High dropout in the microfracture arm (10 patients) limited direct head-to-head comparison, so the trial is best read as confirming ChondroFiller's efficacy rather than establishing superiority over surgery.

One biomechanical finding from a 2024 in-vitro study warrants an honest mention: under full cyclic loading in a laboratory model, the gel's early-phase instability meant it did not immediately protect adjacent cartilage. The authors' recommendation — delay full weight-bearing until stable defect filling is achieved — directly informs the post-injection rehabilitation protocol our consultants use. It does not undermine the treatment; it defines how to get the most from it.

Longer-term randomised trial data specific to the knee remain limited, and the field would benefit from larger controlled studies with extended follow-up.

The injection appointment and recovery after ChondroFiller

The outpatient appointment at MSK Doctors follows a straightforward sequence. Before any injection is considered, the consulting team reviews existing MRI to confirm defect size, grade, and anatomical location; where onMRI™ AI-assisted analysis has been used during the diagnostic workup, that assessment informs the pre-injection conversation.

The injection itself is delivered under real-time ultrasound guidance — no theatre, no general anaesthetic, no overnight stay. Ultrasound allows the clinician to watch the collagen scaffold enter the defect and confirm precise, flush placement, which the evidence shows directly affects the quality of repair tissue formed. The gel sets within minutes of contact, bonding to the defect walls without the need to dry or debride the surrounding joint.

Post-injection, weight-bearing is managed gradually. Because the gel requires time to stabilise mechanically before tolerating full cyclic load — a principle covered by the 2024 in-vitro data and built into the protocol — patients are typically guided through a phased return to normal activity rather than walking out unrestricted. This is standard practice, not a cause for concern; it simply reflects how the scaffold matures.

Functional gains tend to follow a similar trajectory to the MRI data: most improvement comes through months three to six, with the repair continuing to consolidate through the first year. Patients should expect a gradual, progressive recovery rather than an immediate step-change after the appointment.

How ChondroFiller sits alongside other options for post-meniscus knee pain

Knowing where ChondroFiller sits among other injection options makes the decision clearer — because the injections described below are doing fundamentally different jobs.

ChondroFiller is the regenerative scaffold in this menu. Its purpose is to promote the body's own repair of the defect itself through acellular matrix-induced chondrogenesis — not to cushion symptoms or lubricate the joint. That distinction matters when comparing it with the alternatives.

PRP (platelet-rich plasma) works through a different mechanism — modulating the joint's biological environment rather than providing a structural scaffold. It may be used earlier in the care pathway for milder symptoms, or as a complementary treatment alongside ChondroFiller where the clinical picture warrants it; the two should not be conflated as equivalent injections.

Hyaluronic acid (HA) / viscosupplementation addresses pain and stiffness through joint lubrication. It does not repair focal cartilage defects, and it is not a substitute for scaffold treatment where a structural lesion has been identified.

Arthrosamid® (PAAG hydrogel) is a long-lasting hydrogel licensed for symptomatic knee osteoarthritis. As a permanent intra-articular filler it addresses a different clinical problem from a focal chondral defect, and it carries no regenerative mechanism.

Surgical options — including ACI and osteochondral grafting — remain appropriate for larger or more complex defects, particularly where ChondroFiller's Grade I–III focal indication is exceeded. They carry significantly greater recovery demands and are typically considered at a higher severity threshold.

For patients exploring these options after a meniscus injury, a consultant assessment is the right starting point. You can book at MSK Doctors without a referral at mskdoctors.com.

1. [1] Concomitant medial meniscus tear and focal chondral defect of the medial femoral condyle. (2006). https://doi.org/10.1007/978-0-387-38299-9_5 https://doi.org/10.1007/978-0-387-38299-9_5
2. [2] Implantation of ChondroFiller Liquid® as a Scaffold Material for Treatment of Chondral Lesions of the Knee Joint. (2024). https://doi.org/10.5272/jimab.2024304.5936 https://doi.org/10.5272/jimab.2024304.5936
3. [3] Controlled, randomized multicenter study: ChondroFiller liquid vs microfracturing for focal cartilage defects of the knee. (2016). https://doi.org/10.5348/VNP05-2016-1-OA-1 https://doi.org/10.5348/VNP05-2016-1-OA-1
4. [4] Arthroscopic utilization of ChondroFiller gel for treatment of hip articular cartilage defects: cohort study with 12–60-month follow-up. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002
5. [5] Combined autologous chondrocyte implantation and meniscus reconstruction for large chondral defect due to discoid lateral meniscus tear. (2018). https://doi.org/10.1016/j.reth.2018.11.002 https://doi.org/10.1016/j.reth.2018.11.002
6. [6] Development of an Ex Vivo Osteochondral Biomimetic Platform for Mechanistic Investigation of Cartilage Regeneration. (2025). https://doi.org/10.3390/ijms262311759 https://doi.org/10.3390/ijms262311759
7. [7] Cartilage reconstruction using Chondrofiller in intra-articular distal radius fractures. (2025). https://doi.org/10.1186/s42836-025-00333-y https://doi.org/10.1186/s42836-025-00333-y
8. [8] Influence of cartilage defects and a collagen gel on integrity of corresponding intact cartilage: a biomechanical in-vitro study. (2024). https://doi.org/10.1007/s00402-024-05530-z https://doi.org/10.1007/s00402-024-05530-z